Literature DB >> 16373342

Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts.

Hiroyuki Kaneki1, Ruolin Guo, Di Chen, Zhenqiang Yao, Edward M Schwarz, Ying E Zhang, Brendan F Boyce, Lianping Xing.   

Abstract

Tumor necrosis factor (TNF) plays an important role in the pathogenesis of inflammatory bone loss through stimulation of osteoclastic bone resorption and inhibition of osteoblastic bone formation. Compared with the well established role of TNF in osteoclastogenesis, mechanisms by which TNF inhibits osteoblast function have not been fully determined. Runx2 is an osteoblast-specific transcription factor whose steady-state protein levels are regulated by proteasomal degradation, mediated by the E3 ubiquitin ligases, Smurf1 and Smurf2. We hypothesized that TNF inhibits osteoblast function through Smurf-mediated Runx2 degradation. We treated C2C12 and 2T3 osteoblast precursor cell lines and primary osteoblasts with TNF and found that TNF, but not interleukin-1, significantly increased Smurf1 and Smurf2 expression. TNF increased the degradation of endogenous or transfected Runx2 protein, which was blocked by treating cells with a proteasomal inhibitor or by infecting cells with small interfering (si)RNA against Smurf1 or Smurf2. TNF inhibited the expression of bone morphogenetic protein and transforming growth factor-beta signaling reporter constructs, and the inhibition of each was blocked by Smurf1 siRNA and Smurf2 siRNA, respectively. Overexpression of Smurf1 and/or Smurf2 siRNAs prevented the inhibitory effect of TNF on Runx2 reporter. Consistent with these in vitro findings, bones from TNF transgenic mice or TNF-injected wild type mice had increased Smurf1 and decreased Runx2 protein levels. We propose that one of the mechanisms by which TNF inhibits bone formation in inflammatory bone disorders is by promoting Runx2 proteasomal degradation through up-regulation of Smurf1 and Smurf2 expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16373342      PMCID: PMC2647592          DOI: 10.1074/jbc.M509430200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase.

Authors:  Y Zhang; C Chang; D J Gehling; A Hemmati-Brivanlou; R Derynck
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

2.  Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation.

Authors:  P Kavsak; R K Rasmussen; C G Causing; S Bonni; H Zhu; G H Thomsen; J L Wrana
Journal:  Mol Cell       Date:  2000-12       Impact factor: 17.970

3.  Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling.

Authors:  X Lin; M Liang; X H Feng
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

4.  Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival.

Authors:  L Xing; A M Venegas; A Chen; L Garrett-Beal; B F Boyce; H E Varmus; P L Schwartzberg
Journal:  Genes Dev       Date:  2001-01-15       Impact factor: 11.361

Review 5.  Pathogenesis of bone erosions in rheumatoid arthritis.

Authors:  S R Goldring; E M Gravallese
Journal:  Curr Opin Rheumatol       Date:  2000-05       Impact factor: 5.006

6.  Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha.

Authors:  Linda Gilbert; Xiaofei He; Paul Farmer; Janet Rubin; Hicham Drissi; Andre J van Wijnen; Jane B Lian; Gary S Stein; Mark S Nanes
Journal:  J Biol Chem       Date:  2001-11-26       Impact factor: 5.157

7.  Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation.

Authors:  Motozo Yamashita; Sai-Xia Ying; Gen-Mu Zhang; Cuiling Li; Steven Y Cheng; Chu-Xia Deng; Ying E Zhang
Journal:  Cell       Date:  2005-04-08       Impact factor: 41.582

8.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.

Authors:  H Takayanagi; K Ogasawara; S Hida; T Chiba; S Murata; K Sato; A Takaoka; T Yokochi; H Oda; K Tanaka; K Nakamura; T Taniguchi
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

9.  Identification of ubiquitin ligases required for skeletal muscle atrophy.

Authors:  S C Bodine; E Latres; S Baumhueter; V K Lai; L Nunez; B A Clarke; W T Poueymirou; F J Panaro; E Na; K Dharmarajan; Z Q Pan; D M Valenzuela; T M DeChiara; T N Stitt; G D Yancopoulos; D J Glass
Journal:  Science       Date:  2001-10-25       Impact factor: 47.728

10.  Inhibition of osteoblast differentiation by tumor necrosis factor-alpha.

Authors:  L Gilbert; X He; P Farmer; S Boden; M Kozlowski; J Rubin; M S Nanes
Journal:  Endocrinology       Date:  2000-11       Impact factor: 4.736

View more
  130 in total

1.  Differentially expressed genes in PPARγ-deficient MSCs.

Authors:  Yun Su; Xiaona Shen; Jie Chen; Carlos M Isales; Jing Zhao; Xing-Ming Shi
Journal:  Mol Cell Endocrinol       Date:  2017-07-31       Impact factor: 4.102

2.  Role of TNF alpha and PLF in bone remodeling in a rat model of repetitive reaching and grasping.

Authors:  Shobha Rani; Mary F Barbe; Ann E Barr; Judith Litivn
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

Review 3.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

4.  Cyclic AMP Response Element-binding Protein H (CREBH) Mediates the Inhibitory Actions of Tumor Necrosis Factor α in Osteoblast Differentiation by Stimulating Smad1 Degradation.

Authors:  Won-Gu Jang; Byung-Chul Jeong; Eun-Jung Kim; Hyuck Choi; Sin-Hye Oh; Don-Kyu Kim; Seung-Hoi Koo; Hueng-Sik Choi; Jeong-Tae Koh
Journal:  J Biol Chem       Date:  2015-04-14       Impact factor: 5.157

5.  Smurf1 regulates neural patterning and folding in Xenopus embryos by antagonizing the BMP/Smad1 pathway.

Authors:  Evguenia M Alexandrova; Gerald H Thomsen
Journal:  Dev Biol       Date:  2006-08-10       Impact factor: 3.582

Review 6.  [Pharmaceutical therapy of bone metabolism disorders in chronic kidney disease mineral bone disorder (CKD-MBD) with special respect to antiresorptive substances].

Authors:  G Lehmann; G Wolf
Journal:  Z Rheumatol       Date:  2014-05       Impact factor: 1.372

Review 7.  Altered bone remodeling in psoriatic arthritis.

Authors:  Kofi A Mensah; Edward M Schwarz; Christopher T Ritchlin
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

8.  Bone density, structure, and strength in juvenile idiopathic arthritis: importance of disease severity and muscle deficits.

Authors:  Jon M Burnham; Justine Shults; Sarah E Dubner; Harjeet Sembhi; Babette S Zemel; Mary B Leonard
Journal:  Arthritis Rheum       Date:  2008-08

9.  Lipopolysaccharide-induced epithelial monoamine oxidase mediates alveolar bone loss in a rat chronic wound model.

Authors:  Daisuke Ekuni; James D Firth; Tarun Nayer; Takaaki Tomofuji; Toshihiro Sanbe; Koichiro Irie; Tatsuo Yamamoto; Takashi Oka; Zhenzi Liu; Juergen Vielkind; Edward E Putnins
Journal:  Am J Pathol       Date:  2009-09-24       Impact factor: 4.307

10.  Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins.

Authors:  Ruolin Guo; Motozo Yamashita; Qian Zhang; Quan Zhou; Di Chen; David G Reynolds; Hani A Awad; Laura Yanoso; Lan Zhao; Edward M Schwarz; Ying E Zhang; Brendan F Boyce; Lianping Xing
Journal:  J Biol Chem       Date:  2008-06-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.